FIGURE 6 from LP-184, a Novel Acylfulvene Molecule, Exhibits Anticancer Activity against Diverse Solid Tumors with Homologous Recombination Deficiency

LP-184 and Olaparib combination showed synergy in TNBC PDX models. A, The BRCA2-mutated HBCx10 TNBC PDX mouse tumor models were treated with the vehicle (saline), LP-184 (intravenously on days 1 and 8), olaparib (orally daily), or combination of LP-184 and olaparib. Tumor volumes at day 22 were displayed as mean ± SD (N = 3 mice/arm). B, The BRCA1-mutated HBCx28 TNBC PDX mouse tumor models were treated with the vehicle (saline), LP-184 (intravenously on days 1, 4, 8, and 11), olaparib (orally daily), or combination of LP-184 and olaparib. Tumor volumes at day 21 were displayed as mean ± SD (N = 3 mice/arm). Group means were compared using the unpaired t test. ns, not significant. *, P ≤ 0.05; ****, P ≤ 0.0001.